the trading in this stock off the GSK news yesterday tells me, loudly, that the stock is riddled with net shorts, and that some very meaningful portion of the short interest is in fact, not hedged (just like it was NOT on October 12, 2012)
the consenus on Srpt forward prospects appears to be luke warm, at best
if the FDA shifts gears with Srpt, I suspect the stock would at least triple
maybe more, initially, due to the unhedged shorts in this stock
unfortunately, the stock has been riddled by unhedged , large shorts for as long as I can remember. So far, they are 1 out of 2, in that they had their shorts handed to them 10/12, but got more than lucky when the FDA erroneously determined that GSK's data implied there wasn't a direct correlation between dystrophin production and clinical benefi.............. How will things play out this time around? I think these aggressive shorts are probably the original group who lost HUGE on 10/12, and they've been angling to make back what they lost ever since, at any cost.
Cmon FDA..........................make my day. Admit you were premature in your conclusions, and do the right thing, not the least of which would be to help shed SRPT of these vultures.